Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s...
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:...
Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société de biotechnologie de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes...
Consolidated revenue of €3.4m at the end of September 2024 Cash position of €4.1m before receipt of IRIS Pharma’s CIR (€610k) as of September 30, 2024 Live broadcast of the General Meeting on...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.026 | -2.04724409449 | 1.27 | 1.284 | 1.194 | 14363 | 1.26172408 | DE |
4 | 0.044 | 3.66666666667 | 1.2 | 1.34 | 1.16 | 29679 | 1.27152706 | DE |
12 | -0.106 | -7.85185185185 | 1.35 | 1.422 | 1.16 | 37566 | 1.29119289 | DE |
26 | 0.024 | 1.96721311475 | 1.22 | 1.5 | 1.128 | 39111 | 1.28804711 | DE |
52 | 0.014 | 1.13821138211 | 1.23 | 1.5 | 0.91 | 48518 | 1.22103126 | DE |
156 | -1.106 | -47.0638297872 | 2.35 | 2.615 | 0.91 | 90276 | 1.67961698 | DE |
260 | 0.869 | 231.733333333 | 0.375 | 3.57 | 0.368 | 240565 | 1.43616232 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관